scholarly journals Selective Advantage of the Recurrent Isodicentric Chromosome 20 in Myeloid Disease

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5119-5119
Author(s):  
Justin B Schleede ◽  
Peter Papenhausen ◽  
Stuart Schwartz ◽  
Inder K. Gadi

Abstract Interstitial deletion of the long arm of chromosome 20 is a common genomic imbalance associated with myeloid hematologic disorders. Originally identified by conventional cytogenetics and fluorescent in situ hybridization, it has been hypothesized that deletion of 20q results in haploinsuffciency of tumor suppressor gene(s) causing a proliferative advantage. The advent of microarray analysis has revolutionized the detection of copy number gains and losses associated with a variety of oncogenic mechanisms. Initial studies using microarray analysis have shown significant heterogeneity in the breakpoints associated with interstitial deletions of 20q, ruling out the possibility of a recurrent genomic fusion, but establishing a critical region which appears to support a tumor suppressor gene loss model. We have documented six individuals, referred for microarray analysis of myelodysplasia, with alterations of chromosome 20 involving a similar complex rearrangement. The rearrangement is an isodicentric chromosome 20 consisting of 1) a deletion of the majority of the short arm pter to p11.1, 2) retention of the region flanking the centromere from p11.1 to q11.21, and 3) an adjacent interstitial deletion of the long arm that can vary in size similar to the common 20q deletion. The breakpoints of the region flanking the centromere at 20p11.1 are within a block of segmental repeats and virtually identical in all 6 cases while the break points in 20q11.21 are within ~1.1 MB (30,785,977-31,887,129). In addition, one of the six cases shows additional copies of the region flanking the centromere from p11.1 to q11.21 consistent with supernumerary marker chromosomes found by conventional cytogenetics. These results suggest that there is a selective advantage associated with a gene(s) within the chromosome 20p11.1->q11.21 segment. The PDRG1 gene is localized to 20q11.21and has been shown to be upregulated in number of malignant cell types including colon, rectum, ovary, lung, stomach, breast and uterus. As our results show, PDRG1 is duplicated or amplified in all 6 cases with the isodicentric chromosome 20. Therefore, these results suggest PDRG1 upregulation may contribute to the pathogenicity of myelodysplasia by conferring a selective advantage in individuals with the isodicentric chromosome 20. Disclosures No relevant conflicts of interest to declare.

2001 ◽  
Vol 120 (5) ◽  
pp. A299-A299
Author(s):  
D KAZANOV ◽  
B STERN ◽  
W PYERIN ◽  
O BOECHER ◽  
H STRUL ◽  
...  

Neurographics ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 228-235
Author(s):  
S. Naganawa ◽  
T. Donohue ◽  
A. Capizzano ◽  
Y. Ota ◽  
J. Kim ◽  
...  

Li-Fraumeni syndrome is a familial cancer predisposition syndrome associated with germline mutation of the tumor suppressor gene 53, which encodes the tumor suppressor p53 protein. Affected patients are predisposed to an increased risk of cancer development, including soft-tissue sarcomas, breast cancer, brain tumors, and adrenocortical carcinoma, among other malignancies. The tumor suppressor gene TP53 plays an important, complex role in regulating the cell cycle, collaborating with transcription factors and other proteins. The disruption of appropriate cell cycle regulation by mutated TP53 is considered to be the cause of tumorigenesis in Li-Fraumeni syndrome. Appropriate surveillance, predominantly by using MR imaging, is used for early malignancy screening in an effort to improve the survival rate among individuals who are affected. Patients with Li-Fraumeni syndrome are also at increased risk for neoplasm development after radiation exposure, and, therefore, avoiding unnecessary radiation in both the diagnostic and therapeutic settings is paramount. Here, we review the epidemiology, genetics, imaging findings, and the current standard surveillance protocol for Li-Fraumeni syndrome from the National Comprehensive Cancer Network as well as potential treatment options.Learning Objective: Describe the cause of second primary malignancy among patients with Li-Fraumeni syndrome.


Sign in / Sign up

Export Citation Format

Share Document